Fox Mark, Stutz Bernadette, Menne Dieter, Fried Michael, Schwizer Werner, Thumshirn Miriam
Department of Gastroenterology, St. Thomas' Hospital, London, UK.
Dig Dis Sci. 2005 Sep;50(9):1576-83. doi: 10.1007/s10620-005-2900-6.
Continence problems during treatment with orlistat (a lipase inhibitor) are caused when susceptible patients are exposed to increased volumes of loose, fatty stool.
To investigate the dose-response effects of loperamide on continence and anorectal function in subjects susceptible to continence problems on orlistat.
Ten obese subjects enterred a randomized controlled, double-blind study of loperamide at placebo, 2, 4, and 6 mg/day in a factorial design. Continence problems during orlistat treatment were self-assessed by patient diary. Anorectal function and continence were assessed by barostat, manometry, and retention testing.
Loperamide increased stool consistency with dose (p = 0.07) and this effect reduced continence problems during orlistat treatment (p < 0.05). A bell-shaped dose-response relationship was present with anal sphincter function (p < 0.01) and anorectal sensitivity (p < 0.01).
Loperamide has beneficial effects on stool consistency and continence in obese subjects taking orlistat. The effect on stool consistency appeared more important than effects on anorectal function.
当易患失禁问题的患者接触到更多量的松散、油腻粪便时,就会在服用奥利司他(一种脂肪酶抑制剂)治疗期间出现失禁问题。
研究洛哌丁胺对服用奥利司他易出现失禁问题的受试者的控便能力和肛肠功能的剂量反应效应。
10名肥胖受试者进入一项采用析因设计、关于洛哌丁胺(安慰剂、每日2毫克、4毫克和6毫克)的随机对照双盲研究。奥利司他治疗期间的失禁问题由患者日记进行自我评估。通过压力测定仪、测压法和潴留测试评估肛肠功能和控便能力。
洛哌丁胺使粪便稠度随剂量增加(p = 0.07),且这种效应减少了奥利司他治疗期间的失禁问题(p < 0.05)。肛门括约肌功能(p < 0.01)和肛肠敏感性(p < 0.01)呈现钟形剂量反应关系。
洛哌丁胺对服用奥利司他的肥胖受试者的粪便稠度和控便能力有有益影响。对粪便稠度的影响似乎比对肛肠功能的影响更重要。